Faculty Information - MIZOGUCHI Shinsuke

（Last updated : 2026-07-28 13:32:10）

MIZOGUCHI Shinsuke
Department Other, Other Department of Urology

Position

■ Published papers

1.	Original article	Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
2.	Original article	Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
3.	Other	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN. 2026/05
4.	Original article	Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
5.	Original article	Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
6.	Original article	Treatment profile of first-line immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma in patients with end-stage renal disease on dialysis. 2026/01
7.	Original article	Renal function with enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan. 2025/12
8.	Original article	Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
9.	Original article	Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
10.	Case report	Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases. 2025/08
11.	Original article	Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
12.	Other	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2025/05
13.	Original article	Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
14.	Original article	Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan. 2025/04
15.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
16.	Original article	Robot-assisted partial nephrectomy for multiple allograft renal cell carcinomas: A case report. 2024/11
17.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
18.	Original article	Robot-assisted partial nephrectomy with selective artery clamping for renal cell carcinoma in horseshoe kidney. 2024/07
19.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
20.	Case report	Advanced renal cell carcinoma with Inferior vena cava thrombus treated with a combination of preoperative lenvatinib and pembrolizumab. 2024/03
Display 5 items
Display all(20)

■ Academic conference presentation

1.	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN （Poster notice，General） 2026/05/16
2.	Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （Poster notice，General） 2026/04/23
3.	Mid-term real-world outcome of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs for renal cell carcinoma using minimum 3-year follow-up data. （Speech，General） 2026/04/23
4.	Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
5.	Impact of cytoreductive nephrectomy on immunecheckpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies formetastatic renal cell carcinoma with primary kidneytumors. （Poster notice，General） 2025/04/28
6.	BRCA mutation-positive prostate cancer at our hospital initial experience with olaparib in BRCA mutation-positive prostate cancer. （Poster notice，General） 2024/04/26
7.	Efficiency of IO-IO combination therapy and IO-TKI combination therapy for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice） 2024/04/26
8.	Utility of whole-body MRI (DWIBS) in treatment decision-making for M0CRPC: A case series study. （Poster notice，General） 2024/04/26
9.	Comparison of Perioperative Outcomes between Robot-Assisted Laparoscopic Radical Nephroureterectomy and Laparoscopic Radical Nephroureterectomy. （Poster notice） 2024/04/25
10.	Comparison of surgical outcomes between robot-assisted and conventional laparoscopic adrenalectomy at Tokyo Women's Medical University Hospital. （Poster notice，General） 2024/04/25
11.	Evaluation of cases of cytomegalovirus infection after renal transplantation at our department. （Speech，General） 2022/11/25
Display 5 items
Display all(11)